124 related articles for article (PubMed ID: 28905988)
1. Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations.
Cox D; Fitzgerald DJ
Clin Pharmacol Ther; 2018 Jun; 103(6):1047-1051. PubMed ID: 28905988
[TBL] [Abstract][Full Text] [Related]
2. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
Cox D; Maree AO; Dooley M; Conroy R; Byrne MF; Fitzgerald DJ
Stroke; 2006 Aug; 37(8):2153-8. PubMed ID: 16794200
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence assessment of two enteric-coated aspirin brands, Nu-Seals and Loprin, after a single oral dose of 150 mg in healthy male adults.
Bukhari NI; Zafar A; Shamsi Wu; Bashir MA; Mirza AA
Therapie; 2005; 60(2):167-73. PubMed ID: 15969319
[TBL] [Abstract][Full Text] [Related]
4. Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood.
Stampfer MJ; Jakubowski JA; Deykin D; Schafer AI; Willett WC; Hennekens CH
Am J Med; 1986 Sep; 81(3):400-4. PubMed ID: 3529953
[TBL] [Abstract][Full Text] [Related]
5. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid.
Haastrup PF; Grønlykke T; Jarbøl DE
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):212-5. PubMed ID: 25469781
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes.
Cerletti C; Dell'Elba G; Manarini S; Pecce R; Di Castelnuovo A; Scorpiglione N; Feliziani V; de Gaetano G
Clin Pharmacokinet; 2003; 42(12):1059-70. PubMed ID: 12959636
[TBL] [Abstract][Full Text] [Related]
7. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
[TBL] [Abstract][Full Text] [Related]
8. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
9. A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy.
Shanmugalingam R; Wang X; Münch G; Fulcher I; Lee G; Chau K; Xu B; Kumar R; Hennessy A; Makris A
Am J Obstet Gynecol; 2019 Sep; 221(3):255.e1-255.e9. PubMed ID: 31051121
[TBL] [Abstract][Full Text] [Related]
10. Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation.
Charman WN; Charman SA; Monkhouse DC; Frisbee SE; Lockhart EA; Weisman S; Fitzgerald GA
Br J Clin Pharmacol; 1993 Nov; 36(5):470-3. PubMed ID: 12959298
[TBL] [Abstract][Full Text] [Related]
11. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
[TBL] [Abstract][Full Text] [Related]
12. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus.
Bhatt DL; Grosser T; Dong JF; Logan D; Jeske W; Angiolillo DJ; Frelinger AL; Lei L; Liang J; Moore JE; Cryer B; Marathi U
J Am Coll Cardiol; 2017 Feb; 69(6):603-612. PubMed ID: 28089180
[TBL] [Abstract][Full Text] [Related]
13. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
[TBL] [Abstract][Full Text] [Related]
14. Low-dose enteric-coated aspirin as an antiplatelet preparation.
McLeod LJ; Roberts MS; Seville PR
Med J Aust; 1988 Feb; 148(4):207. PubMed ID: 3340049
[No Abstract] [Full Text] [Related]
15. Influence of low dose enteric-coated aspirin on platelet function.
Rao GH; Rao AS; White JG
Indian Heart J; 1992; 44(6):365-70. PubMed ID: 1307083
[TBL] [Abstract][Full Text] [Related]
16. The antiplatelet effect of daily low dose enteric-coated aspirin in man: a time course of onset and recovery.
Vanags D; Rodgers SE; Lloyd JV; Bochner F
Thromb Res; 1990 Sep; 59(6):995-1005. PubMed ID: 2264023
[TBL] [Abstract][Full Text] [Related]
17. Aspirin resistance.
Tantry US; Mahla E; Gurbel PA
Prog Cardiovasc Dis; 2009; 52(2):141-52. PubMed ID: 19732606
[No Abstract] [Full Text] [Related]
18. Alditols and monosaccharides from sorghum vinegar can attenuate platelet aggregation by inhibiting cyclooxygenase-1 and thromboxane-A2 synthase.
Li J; Yu G; Fan J
J Ethnopharmacol; 2014 Aug; 155(1):285-92. PubMed ID: 24877847
[TBL] [Abstract][Full Text] [Related]
19. Aspirin: expectations and limitations.
Rao GH
J Assoc Physicians India; 2008 May; 56():317-9. PubMed ID: 18700637
[No Abstract] [Full Text] [Related]
20. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
